Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$120.18 USD

120.18
1,185,820

-1.05 (-0.87%)

Updated May 17, 2024 04:03 PM ET

After-Market: $120.14 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Zimmer Biomet Grows Internationally Despite Pricing Pressure

by Zacks Equity Research

Zimmer Biomet (ZBH) witnesses strength in the EMEA and APAC regions as well as in the Spine & CMF business.

Why Is Zimmer (ZBH) Down 8.2% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates

by Urmimala Biswas

While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.

Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

by Zacks Equity Research

With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.

Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings

by Zacks Equity Research

With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.

Zimmer Biomet Solid on Global Prospects Despite Price Pressure

by Zacks Equity Research

Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.

RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio

by Zacks Equity Research

RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.

Zimmer Biomet (ZBH) Jumps: Stock Rises 6.4%

by Zacks Equity Research

Zimmer Biomet (ZBH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top

by Zacks Equity Research

Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.

Zimmer Biomet (ZBH) Meets Q4 Earnings Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 0.00% and 0.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions

by Zacks Equity Research

The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.

Medical Products Industry Outlook: Plenty of Upside Left

by Zacks Equity Research

The growing adoption of AI, Medical Mechatronics & Robotics has lent the Medical Products industry a competitive edge in the broader medical market.

Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?

by Zacks Equity Research

Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.

Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?

by Zacks Equity Research

Let's see if Zimmer Biomet (ZBH) stock is a good choice for value-oriented investors right now from multiple angles.

Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.

Zimmer Biomet Rides on New Operational Plan Amid Several Woes

by Zacks Equity Research

In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.

Should Value Investors Pick Zimmer Biomet (ZBH) Stock?

by Zacks Equity Research

Is Zimmer Biomet (ZBH) a great pick from the value investor's perspective right now? Read on to know more.

Zimmer (ZBH) Down 7.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet

Mark Vickery headshot

Top Research Reports for Comcast, ConocoPhillips & Delta Air Lines

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), ConocoPhillips (COP), and Delta Air Lines (DAL).

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.

Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 1.87% and 0.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Zimmer Biomet (ZBH) This Earnings Season?

by Zacks Equity Research

Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.